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Protocol
AbstrACt
Introduction Active surveillance is a strategy for 
managing low-risk, localised prostate cancer, where 
men are observed with serial prostate-specific antigen 
assessments to identify signs of disease progression. 
Currently, there are no strategies to support active 
surveillance compliance nor are there interventions that 
can prevent or slow disease progression, ultimately 
delaying transition to active treatment before it is clinically 
required. Recently, we proposed that exercise may have 
a therapeutic potential in delaying the need for active 
treatment in men on active surveillance.
Methods and analysis A single-blinded, two arm, 
multicentre randomised controlled trial will be undertaken 
with 168 patients randomly allocated in a ratio of 1:1 to 
exercise or usual care. Exercise will consist of supervised 
resistance and aerobic exercise performed three times per 
week for the first 6 months in an exercise clinical setting, 
and during months 7–12, a progressive stepped down 
approach will be used with men transitioning to once a 
week supervised training. Thereafter, for months 13 to 
36, the men will self-manage their exercise programme. 
The primary endpoint will be the time until the patients 
begin active therapy. Secondary endpoints include disease 
progression (prostate specific antigen), body composition 
and muscle density, quality of life, distress and anxiety and 
an economic analysis will be performed. Measurements 
will be undertaken at 6 and 12 months (postintervention) 
and at 24 and 36 months follow-up. The primary outcome 
(time to initiation of curative therapy) will be analysed 
using Cox proportional hazards regression. Outcomes 
measured repeatedly will be analysed using mixed effects 
models to examine between-group differences. Data will 
be analysed using an intention-to-treat approach.
Ethics and dissemination Outcomes from the study 
will be published in peer-reviewed academic journals and 
presented in scientific, consumer and clinical meetings.
trial registration number ACTRN12618000225213.
IntroduCtIon 
Prostate cancer (PCa) is a major challenge 
for our health system and its workforce and 
for Australian society as a whole. In 2017, 
more than 200 000 Australian men were 
living with PCa, 80% of them were long-
term survivors.1 2 The widespread pros-
tate-specific antigen (PSA) screening for 
PCa has led to concerns about the overdiag-
nosis and overtreatment of this disease with 
the overdiagnosis estimated to be as high as 
67%.3 Overtreatment rates are also high with 
reports of 80% of men receiving treatments 
on initial diagnosis.4 Active surveillance (AS) 
is a strategy for managing low-risk localised 
PCa, where men are observed with regularly 
schedule serial PSA assessments to identify 
signs of disease progression.5 AS reduces over-
treatment in clinically insignificant disease,5 
reducing PCa burden for the individual, the 
healthcare system and the society. Problemat-
ically, most men will not comply with AS and 
those who convert to active treatment too 
strengths and limitations of this study
 ► This is a novel multicentre randomised controlled 
trial of 12-month supervised resistance and aero-
bic exercise versus usual care in men with prostate 
cancer on active surveillance, with subsequent fol-
low-up of over 2 years to monitor therapeutic pro-
gression and psychological well-being.
 ► The study proposed here will determine the effica-
cy of a comprehensive exercise programme during 
active surveillance in delaying or preventing patient 
morbidity associated with prostate cancer primary 
therapy. Savings to the health and medical system 
could be extensive with any delay in prostatec-
tomy, radiation therapy or androgen deprivation 
therapy, reducing costs of current overtreatment 
substantially.
 ► The study will be undertaken in the Australian clin-
ical setting of prostate cancer care, and differenc-
es in active surveillance and disease progression 
definitions may exist within the context of other 
countries.
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soon. Currently there are no strategies to (1) support AS 
compliance applying a lifestyle approach or (2) prevent or 
slow disease progression, ultimately delaying transition to 
active treatment before it is clinically required.5–10 These 
are the two critical unanswered questions in applying AS 
to men with PCa.
We recently presented a preliminary evidence6 that 
exercise may have therapeutic potential in delaying the 
need for active treatment (eg, surgery/radiation) in men 
on AS. Exercise is implicated in decreasing the number of 
patients undergoing active treatment,11 reducing PSA,12 
as well as modulating the biological processes involved 
with tumourigenesis.13 It may act through systemic mech-
anisms, as exercise alters circulating factors that inhibit 
PCa cell proliferation in vitro.14–16 Further, increased 
adiposity is associated with increased risk of PCa 
progression specifically during AS,17 and exercise can be 
an effective countermeasure to this in the setting of AS 
(figure 1).6
Exercise as a therapeutic intervention in such men may 
also have important additional benefits by addressing 
other adverse consequences. The psychological burden 
of AS, in terms of cancer-related anxiety, also influences 
adherence and treatment decisions as much as clinical 
disease progression.18 Not treating a cancer runs against 
the norm and the surveillance process is inherently 
stressful. Exercise presents as a supportive care approach 
that closely maps onto core male values and has the poten-
tial to both combat illness but also help prevent and/or 
minimise anxiety and uncertainty related to living with 
a PCa diagnosis. Specifically, by supporting male values 
around strength, self-reliance and action,19 exercise may 
Figure 1 Proposed mechanisms of exercise on prostate cancer and disease progression. Reprinted with permission from 
Galvao et al.6 
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increase men’s self-efficacy or feelings of control over 
their health, and thereby support adherence to AS while 
improving psychological outcomes and physical and 
mental quality of life (QoL).6 20
To characterise and quantify the benefits of exercise 
for men on AS, we propose to undertake a multicentre 
randomised controlled trial (RCT) of 12-month super-
vised resistance and aerobic exercise versus usual care in 
men with PCa on AS, with subsequent follow-up of over 2 
years to monitor therapeutic progression and psycholog-
ical well-being.
MEthods And AnAlysIs
This is a single-blinded (investigators blinded to group 
allocation), two-arm, multicentre RCT that will examine 
the efficacy of combined resistance and aerobic exercise 
during AS on disease progression in men with low-risk 
PCa. An ‘exercise’ group will complete a 6-month super-
vised exercise intervention followed by a stepped down 
programme for 6 months and a subsequent self-managed 
maintenance programme for 2 years (figure 2). A ‘usual 
care’ group will maintain usual medical care and receive 
standard information on current physical activity guide-
lines for cancer survivors, which will include an unsuper-
vised walking programme.
Patients and methods
One hundred and sixty-eight men (84 patients per arm) 
within 1 year of diagnosis of PCa and undergoing AS will 
be recruited by invitation of their attending specialist from 
two Australian cities (Perth and Melbourne). Patients suit-
able for AS will be selected from the Multi-Disciplinary 
Uro-Oncology meeting at the recruiting site. Inclusion 
criteria are: (1) histologically proven adenocarcinoma of 
the prostate, (2) no prior therapy for PCa, (3) fit for cura-
tive intent therapy, (4) willing to attend follow-up, (5) clin-
ical stage <T2, (6)<10% Gleason pattern 4 disease on biopsy 
and (7) PSA ≤10 ng/mL. Exclusion criteria are: (1) already 
performing regular exercise defined as undertaking struc-
tured resistance and aerobic training two or more times 
per week within the past 3 months, (2) acute illness or any 
musculoskeletal, cardiovascular or neurological disorder 
that could inhibit exercise performance or put participants 
at risk from exercising, (3) variant histopathology (small 
cell, intraductal, sarcomatoid), presence of extrapros-
tatic extension or lymphovascular invasion, (4) patient no 
longer considered a candidate for curative intent treatment 
and (5) intention to move place of residence away from 
the two study sites. Eligible patients will undertake baseline 
measurements prior to randomisation. All patients must 
provide written informed consent prior to participation in 
addition to a physician consent form. The study coordinator 
will obtain the consent forms from patients and physicians. 
All data relevant to the study will be kept on password-en-
crypted computers accessible only by study investigators 
situated in the Exercise Medicine Research Institute (Perth, 
WA, Australia).
Patient and public involvement
We work closely with the Prostate Cancer Foundation of 
Australia (PCFA), their support groups and state offices. 
PCFA and support groups have been involved in the 
development of this proposal and will maintain a very 
important role on this project in patient recruitment and 
support as well as translation and dissemination of the 
research findings. We have used this feedback to inform 
this project and ensure that it engages participants in 
a respectful, ethical and impactful way. As the project 
evolves, PCFA will assist in the dissemination of findings 
to cancer support groups and the general public, while 
study participants will receive their individual results as 
well as overall study findings.
randomisation
Patients will be randomly allocated in a ratio of 1:1 to 
the two study arms, and will be stratified according to: 
(1) age (<60 years≥), (2) PSA (<5≥) and (3) time on AS 
(<6 months≥). Within each stratum, randomisation will 
occur in blocks of either 8 or 10, with block size randomly 
selected in a 1:1 ratio. Patients will be randomised via a 
central web-based service (Griffith University) to ensure 
allocation concealment until study entry. Randomisation 
will occur immediately after each patient completes their 
baseline questionnaire (figure 3). The study coordinator 
will assign participants to groups.
Measurements
All measurement study endpoints will take place at baseline, 
6 months, postintervention (12 months) and 1 and 2-year 
follow-up (months 24 and 36). All assessment tools/proce-
dures have established validity and reliability and are used 
widely in clinical research including by our team.
Primary study endpoint
Patients undergoing active therapy
The number of patients undergoing active therapy 
(radical prostatectomy, radiotherapy or androgen depri-
vation) and the time they began active therapy will be 
extracted directly from the urologist clinical investigators 
Figure 2 Study design (1 year intervention and 1 and 2 years follow-up).
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as part of their routine clinical practice; therefore, all 
patients will be captured. Data will be extracted for the 
3 years following randomisation, and the reasons for 
progression to active therapy will be recorded.
secondary study endpoints
Disease progression (PSA)
For all patients, PSA will be measured commercially by 
an Australian National Association of Testing Authorities 
accredited laboratory.21
Body composition and muscle density
Regional and whole-body lean mass and fat mass will 
be derived from the whole-body dual-energy X-ray 
absorptiometry scans. Trunk adiposity, visceral fat and 
adipose indices will be assessed using standard proce-
dures.21–23 Peripheral quantitative CT will be used to 
measure muscle density (an indicator of fat infiltration 
within the muscle) and muscle cross-sectional areas of the 
lower limbs.24
QoL, prostate cancer-specific distress, overall psychological 
distress and PSA anxiety
Health-related QoL will be assessed using the Medical 
Outcomes Short Form 36 (SF-36v2).25 A three-item cancer 
standardised anxiety scale developed by Latini et al18 will 
assess men’s fears about cancer recurrence. This scale has 
Figure 3 CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials.
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previously been found to predict receipt of active treat-
ment independent of PSA velocity in a sample of men 
on active surveillance.18 Overall cancer-specific distress 
will be assessed by the Impact of Events Scale revised26 
which has been used extensively by our team and is valid 
and reliable in patients with prostate cancer.27 28 The Brief 
Symptom Inventory-18 will be used to assess psychological 
distress across the following domains: anxiety, depression, 
somatisation and global distress severity.29 Antidepressant 
use will be recorded. The Memorial Anxiety Scale for 
Prostate Cancer will be used to assess anxiety specifically 
focused on PSA testing (the PSA Anxiety Subscale).30
Economic analysis
An alongside trial economic evaluation will be under-
taken to assess the health benefits and additional costs 
compared with usual care. This will inform the relative 
value for money of exercise compared with other health-
care interventions in this group of men with PCa. Hospital 
resource use and associated costs will be obtained to assess 
costs for secondary healthcare for the exercise and usual 
care groups. All hospital events, including emergency 
department attendances, outpatient visits and procedures 
and inpatient admission for all causes will be sought. 
These data are important to identify potential PCa-related 
events as well as identifying total healthcare resource use. 
In addition, the costs for providing the exercise interven-
tion will be identified through the study. Data on health 
benefits and costs will be adjusted for covariates such as 
age, key comorbidities (eg, diabetes), body mass index 
and so forth. Health benefits will be measured as quality 
of life via the SF-36v2 and converted to a health utility 
scale using the Australian SF-6D scoring algorithm.31 
Costs associated with health resource use and the costs of 
the intervention will be standardised to a common year 
(eg, 2018). Incremental costs and benefits will then be 
estimated and reported as the incremental cost utility 
ratio (ICUR). The ICUR will be bootstrapped32 to identify 
the 95% CIs, probability the intervention is good value for 
money and the risk of anyone in the intervention group 
not being better off. Deterministic sensitivity analysis will 
be undertaken to identify the main drivers of the costs, 
outcomes and value for money.
Effect mediators
The Masculinity in Chronic Disease Scale19 will assess the 
extent to which men identify with six masculine values: 
strength; sexual importance/priority; family responsi-
bilities; emotional self-reliance; optimistic capacity and 
action approach. This scale was developed for Australian 
men with prostate cancer; has strong evidence of validity 
in this target group and has been found to predict men’s 
help seeking.33 The General Self-Efficacy Scale34 will 
assess men’s perceptions that they can cope with stressful 
life events. This scale has been used widely internationally 
as a predictor of adaptation to adversity including cancer 
treatment effects.20
Other measurements: physical function and physical activity levels
A battery of standard tests will be used to assess phys-
ical function: (1) 400 m walk (aerobic capacity), (2) one 
repetition maximum for the leg press and chest press 
(muscular strength) and (3) repeated chair rise (lower 
body muscle function).21–23 Physical activity levels will 
be assessed objectively over a 7-day period using a vali-
dated, reliable triaxial accelerometer activity monitor 
(ActiGraph GT3X+).35 Self-reported physical activity will 
be assessed by the leisure score index from the Godin 
Leisure-Time Exercise Questionnaire.23 36 37
Safety and monitoring
Patients will be monitored for any adverse events during 
training and testing by the exercise physiologists with 
study clinicians overseeing all aspects of patient manage-
ment where required.
Exercise intervention
The exercise intervention will consist of supervised 
resistance and aerobic exercise performed over three 
sessions per week for 6 months in an exercise clinic 
setting. During months 7–12, the exercise intervention 
group will transition to once a week supervised exercise 
in a clinic for months 7–8, once every 2 weeks supervised 
exercise in months 9–10 and once per month supervised 
exercise in months 11–12. This step-down approach will 
include a self-managed exercise programme consisting 
of a booklet and training log with detailed information 
about the exercise prescription and how to implement 
in a variety of settings. Participants will be encouraged 
and supported to continue their aerobic and resistance 
exercise programme in their local fitness centre or other 
exercise facilities where they can maintain a high-quality 
exercise programme under their self-management. The 
self-managed exercise programme is designed to repli-
cate the exercises performed in the supervised sessions 
and includes resistance, aerobic and flexibility exercises. 
Finally, from month 13 to 36, the exercise programme 
will exclusively consist of a self-managed programme 
and has been implemented by our group previously in 
a multicentre year-long trial in men with PCa on active 
therapy.23 The initial programme will be supervised by 
exercise physiologists in Perth and Melbourne.
The exercise programme is designed to provide optimal 
stimulus to the cardiorespiratory and neuromuscular 
systems while maximising safety, compliance and reten-
tion. The exercise sessions will be conducted in small 
groups of up to 10–12 participants exercising in pairs 
under direct supervision to ensure correct technique 
and minimise the risk for injury. Resistance exercise will 
involve 6–8 exercises that target the major upper and 
lower body muscle groups. Intensity will be manipulated 
from 6 to 12 repetition maximum (RM; ie, the maximal 
weight that can be lifted 6 to 12 times which is equivalent 
to ~60%–85% of 1RM) using one to four sets per exer-
cise. The aerobic exercise component will include 20 to 
30 min of moderate to vigorous intensity cardiovascular 
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exercise (~60%–85% of estimated maximum heart rate) 
using a variety of modes such as walking or jogging on 
a treadmill, cycling or rowing on a stationary ergometer. 
Participants will be encouraged to undertake additional 
aerobic exercise outside the clinic sessions with the goal 
of achieving a total of at least 150 min of moderate to 
vigorous intensity aerobic exercise each week. Exercise 
prescription will be progressive and modified according to 
individual response. Both moderate intensity continuous 
and high-intensity interval training will be implemented 
to provide greater variety and training stimulus. To reduce 
the possibility of boredom and over-reaching, the exer-
cise programme will be periodised by cycling emphasis on 
intensity and volume. We have used this exercise prescrip-
tion effectively in previous trials involving men with PCa 
and have reported significant improvements in quality 
of life, lean muscle mass, fatigue, aerobic capacity and 
physical function.21 23 38–48 The step-down approach to 
self-management is intended to maximise the translation 
of this intervention to best practice management of this 
patient population.
usual care
The usual care group will receive an unsupervised walking 
programme and an educational booklet outlining the 
current national physical activity recommendation for 
cancer survivors along with a logbook to record their 
physical activity. During the study, both groups will be 
encouraged to maintain customary dietary patterns and 
the Mini Nutritional Assessment will be used to monitor 
nutritional status.49
Calculation of sample size
The target sample size of 168 patients is based on having 
80% power to be able to detect a HR of undergoing 
curative therapy in the exercise intervention group, 
compared with the usual care group, of 0.35 or smaller 
(alpha=0.05). This is equivalent to a difference between 
25% of the usual care group undergoing curative therapy 
within 3 years postrandomisation versus <10% in the 
group undertaking the exercise intervention.11 A differ-
ence of this magnitude has been recommended by our 
practice clinicians to be clinically important. This sample 
size accounts for a possible 5% dropout due to clinical 
records not being available at study completion. This 
sample size will give us sufficient power to examine our 
secondary outcomes of interest. For example, for muscle 
mass we will have >80% power to detect differences 
between groups of 0.8 kg or greater at 6 months postin-
tervention, assuming an SD for change of ~1.5 kg and 
30% loss to follow-up (due to the need for participants 
to represent to the study team for this outcome to be 
measured).21
statistical analysis
The primary outcome, initiation of curative therapy, will 
be analysed using Cox proportional hazards regression, 
with treatment group (exercise intervention/usual care) 
entered as the main effect. If data do not meet the propor-
tional hazards assumption, the log-rank test will be used. 
Outcomes measured repeatedly will be analysed using 
mixed-effects models to examine differences between 
groups over time, with treatment group and time included 
as main effects, as well as an intervention-by-time interac-
tion term. The patient will be included as a random effect 
to account for the non-independence of observations 
from the same participant. Continuous outcomes will 
be analysed using linear models, binary outcomes with 
logistic models and count outcomes with Poisson models. 
Depending on the balance between groups postrandomi-
sation, clinically relevant covariates will be included in the 
models where appropriate. Data will be analysed using an 
intention-to-treat approach. Tests will be two tailed and 
an alpha level of 0.05 will be applied as the criterion for 
statistical significance.
EthICs And dIssEMInAtIon
Outcomes from the study will be published in peer-re-
viewed academic journals and presented in scientific, 
consumer and clinical meetings. The study investigators 
and trial coordinator will have access to the data.
dIsCussIon
PCa is a financial burden to men and their families and 
our health system. In 2008 and 2009, this was the top male 
cancer cost to the health system in Australia, totalling 
$A347 million or 14% of total male cancer expenditure.50 
As PCa prevalence increases, the health system will find 
it increasingly difficult to prioritise care in the absence 
of clearly developed economic models. There is a deep-
ening realisation by clinicians and patients that many 
prostate cancers do not require active treatment, and in 
fact, such interventions may result in devastating adverse 
effects. Already, a considerably large number of patients 
are referred for AS.7 51–53 Studies (including our previous 
work) examining the role of exercise in PCa provide 
strong evidence that beneficial effects are derived during 
or following definitive therapy and exercise has recently 
been included in the 2015 PCa Care Guideline: American 
Society of Clinical Oncology Clinical Practice Guideline.7 
There is, however, no information on and evidence base 
for the efficacy of exercise medicine interventions during 
AS in slowing disease progression, reducing anxiety and 
distress and improving QoL. The study proposed here 
would be the first to determine the efficacy of a compre-
hensive exercise programme during AS in substantially 
delaying or preventing patient morbidity associated with 
PCa primary therapy. Savings to the health and medical 
system could be extensive with any delay in prostatec-
tomy, radiation therapy or androgen deprivation therapy 
reducing costs of current overtreatment substantially. If 
proven efficacious in this stage of PCa management, exer-
cise medicine could be immediately implemented as an 
important component of clinical best practice, at minimal 
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cost and with no side effects. This will dramatically reduce 
overtreatment, saving the patient considerable suffering, 
physical pain and possibly extending survival.
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